StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Clinical TrialNov 13, 2026, 10:16 AM

Valneva: Positive Shigella Vaccine Trial Results & 5-Year Chikungunya Vaccine Data

AI Summary

Valneva SE announced positive results from two Phase 2 trials for its Shigella vaccine candidate S4V2, with the CHIM trial meeting its primary endpoint and the infant trial demonstrating favorable immunogenicity and safety. Additionally, five-year follow-up data for its chikungunya vaccine IXCHIQ® showed 94% of participants maintained seroresponse, with comparable antibody persistence across age groups. Valneva is assessing the S4V2 data to plan further development, while the IXCHIQ® data reinforce its potential for long-term protection.

Key Highlights

  • Valneva's Shigella vaccine candidate S4V2 met its primary endpoint in a Phase 2 CHIM trial, showing a statistically significant reduction in shigellosis incidence.
  • Phase 2 infant trial showed S4V2 induced immune responses for all four targeted Shigella serotypes with favorable safety and tolerability.
  • Five-year data for Valneva's chikungunya vaccine IXCHIQ® show 94% of participants maintained seroresponse.
  • Antibody persistence in older adults (65+) for IXCHIQ® was comparable to younger adults.
  • Valneva is evaluating the complete dataset for S4V2 to determine the next steps for development.
  • IXCHIQ®'s five-year data further support its potential for long-term protection after a single vaccination.
  • The chikungunya vaccine IXCHIQ® is being studied for long-term durability of immune responses for up to ten years.
  • A pilot vaccination strategy for IXCHIQ® in Brazil vaccinated nearly 80,000 adults.